Alkermes Initiates Two New Clinical Trials Of ALKS 33
Alkermes, Inc. (NASDAQ: ALKS) announced the initiation of two new clinical trials of ALKS 33, an oral opioid modulator for the potential treatment of addiction and other nervous system disorders. Study ALK33-004 is a phase 1 clinical trial designed to examine the ability of ALKS 33 to block the effects of an opioid following a single oral dose of ALKS 33 in healthy, non-dependent, opioid-experienced subjects.
More: continued here
Filed under: Alcohol / Addiction / Illegal Drugs on May 18th, 2009
You must be logged in to post a comment.